Effects of Exercise by Neuromuscular Stimulation in Dialysis Patients

Dialysis Clinical Trial

Official title:

Effects of Exercise Using Electrical Muscle Stimulation in End Stage Kidney Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03517553
• Other study ID #: 201301731
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 1, 2014
• Est. completion date: June 1, 2020

Study information

• Verified date: May 2018
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators propose a pilot feasibility study to determine if exercise delivered by passive electrical muscle stimulation (EMS) in patients with end stage renal disease (ESRD) on hemodialysis improves physical fitness and insulin resistance, outcome markers associated with morbidity and mortality in this population.

Description:

Subjects who enroll and meet the inclusion and none of the exclusion criteria will first undergo baseline testing including recording of demographic, medical, dialysis and exercise history, taking surveys to assess quality of life and overall mood, measurement of vital signs and anthropomorphic measurements (height, weight, thigh circumference), have blood collected to assess insulin resistance and cytokine levels, measurement of distance walked in 6 minutes and testing of thigh muscle strength.

Subjects will then undergo a 1 month observation period to monitor and optimize their dialysis treatment.

After 1 month the subjects will undergo a repeat assessment of all the baseline testing. They will also undergo a standardized exercise stress test and measurement of body fat and lean body mass with a dual-energy x-ray absorptiometry (DXA) scan.

Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator ("EMPI 300PV" or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.

At 2 and 4 months the subjects will undergo again have repeat assessment of the baseline testing as well as undergoing the standardized exercise stress test and a DXA scan.

At 4 months the subjects will all stop the passive exercise training and then will be followed up 1 month later to repeat assessment of all the baseline testing but will not undergoing the standardized exercise stress test and a DXA scan.

For subjects who agree the investigators will also perform a muscle biopsy under local anesthesia before and 4 hours after the first exercise training session and again at 2 and 4 months. This is used to measure messenger RNA response (gene expression testing) to tell what genes are activated during training.

The efficacy of the exercise training will be assessed by change in aerobic capacity measured by maximal oxygen consumption (peak VO2) and quadriceps muscle strength measured

The primary outcome measure will be whether exercise training improves measures of insulin resistance The investigators will also assess whether there is improvement in other inflammatory and oxidative stress cytokines in the blood stream and whether the training improved their physical performance or overall quality of life.

The total duration of the study for any patient is expected to be 6 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: June 1, 2020
• Est. primary completion date: June 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Able to provide informed consent

2. Currently on maintenance hemodialysis for end stage renal disease and expected to stay in the participating dialysis unit for at least 6 months.

Exclusion Criteria:

1. The presence of a cardiac pacemaker or presence of any other implanted electrical stimulation device

2. Uncontrolled hypertension as defined by a systolic BP >170 mmHg

3. Current presence of unstable angina

4. A heart attack (myocardial infarction) within the last month

5. Expected survival less than 6 months

6. Unsuitable for participation based on physician assessment

7. Pregnancy

8. Unwilling or unable to give informed consent.

Related Conditions & MeSH terms

• Dialysis

Intervention

Device:
• EMS users in ESRD
use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis

Locations

Country	Name	City	State
United States	University of Iowa	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Bradley S. Dixon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Insulin resistance as measured by the serum Leptin-Adiponectin ratio	Serum leptin and adiponectin are measured twice at baseline, after 8 and 16 weeks of exercise and 4 weeks post-exercise by radioimmunoassay after a 12 hour fast. The ratio is a measure of insulin resistance.	Baseline, 8 weeks and 16 weeks while exercising, and 4 weeks post exercise
Secondary	Quadriceps muscle strength measured by a belt-stabilized portable dynamometer	To determine if neuromuscular stimulation improves muscle strength quadriceps muscle strength is measured twice at baseline, at 8 and 16 weeks of exercise and 4 weeks post-exercise using a belt-stabilized portable dynamometer.	Baseline, 8 weeks and 16 weeks while exercising, and 4 weeks post exercise